Your browser is no longer supported. Please, upgrade your browser.
Anavex Life Sciences Corp.
Index- P/E- EPS (ttm)-0.48 Insider Own1.40% Shs Outstand70.59M Perf Week-3.33%
Market Cap1.46B Forward P/E- EPS next Y-0.62 Insider Trans-13.66% Shs Float67.77M Perf Month11.91%
Income-32.20M PEG- EPS next Q-0.08 Inst Own27.90% Short Float7.57% Perf Quarter2.21%
Sales- P/S- EPS this Y16.00% Inst Trans-3.92% Short Ratio6.42 Perf Half Y56.22%
Book/sh2.23 P/B8.72 EPS next Y-20.40% ROA-38.00% Target Price38.29 Perf Year274.04%
Cash/sh2.09 P/C9.29 EPS next 5Y- ROE-42.00% 52W Range4.51 - 31.50 Perf YTD260.19%
Dividend- P/FCF- EPS past 5Y7.10% ROI- 52W High-38.25% Beta0.61
Dividend %- Quick Ratio17.90 Sales past 5Y- Gross Margin- 52W Low330.79% ATR1.36
Employees20 Current Ratio17.90 Sales Q/Q- Oper. Margin- RSI (14)46.74 Volatility10.80% 7.07%
OptionableYes Debt/Eq0.00 EPS Q/Q-31.40% Profit Margin- Rel Volume0.99 Prev Close18.99
ShortableYes LT Debt/Eq0.00 EarningsNov 24 BMO Payout- Avg Volume799.11K Price19.45
Recom1.80 SMA20-7.13% SMA502.26% SMA20013.70% Volume787,634 Change2.42%
Sep-23-21Initiated BTIG Research Buy $35
Dec-16-20Reiterated H.C. Wainwright Buy $14 → $17
Sep-28-20Initiated Ladenburg Thalmann Buy $12
Feb-27-20Initiated Cantor Fitzgerald Overweight
Jun-18-19Initiated Janney Buy
May-16-18Resumed Maxim Group Buy $5 → $7
Mar-08-18Initiated ROTH Capital Buy $6
Feb-13-18Reiterated Maxim Group Buy $14 → $5
Sep-29-17Resumed Noble Financial Buy $15
Feb-07-17Initiated Noble Financial Buy $16
Mar-29-16Initiated FBR Capital Outperform $10
Nov-24-21 07:00AM  
Nov-17-21 07:00AM  
Nov-10-21 07:00AM  
Oct-18-21 07:45AM  
Oct-15-21 07:00AM  
Oct-13-21 07:00AM  
Sep-27-21 09:30AM  
Sep-20-21 07:00AM  
Sep-09-21 07:00AM  
Aug-26-21 07:00AM  
Aug-19-21 09:49AM  
Aug-13-21 06:00AM  
Aug-12-21 07:00AM  
Aug-05-21 07:00AM  
Aug-04-21 07:00AM  
Jul-29-21 03:30PM  
Jul-27-21 01:24PM  
Jul-26-21 01:44PM  
Jul-09-21 06:49AM  
Jun-29-21 09:34AM  
Jun-28-21 12:33PM  
Jun-26-21 07:34AM  
Jun-24-21 04:15PM  
Jun-23-21 11:08AM  
Jun-22-21 07:00AM  
Jun-21-21 05:37PM  
Jun-18-21 10:57AM  
Jun-16-21 12:24PM  
Jun-15-21 04:09PM  
Jun-14-21 06:51PM  
Jun-08-21 07:00AM  
Jun-03-21 08:30AM  
May-26-21 07:00AM  
May-14-21 01:30PM  
May-13-21 02:30PM  
May-11-21 08:37AM  
May-07-21 07:00AM  
May-06-21 07:00AM  
May-05-21 07:00AM  
Apr-26-21 07:00AM  
Apr-22-21 12:05PM  
Apr-12-21 07:00AM  
Apr-08-21 07:00AM  
Apr-07-21 07:00AM  
Mar-31-21 07:00AM  
Mar-16-21 07:00AM  
Mar-12-21 08:00AM  
Mar-11-21 07:00AM  
Mar-04-21 07:00AM  
Feb-28-21 11:39PM  
Feb-22-21 07:00AM  
Feb-19-21 07:00AM  
Feb-18-21 07:00AM  
Feb-11-21 10:01PM  
Feb-10-21 10:21AM  
Feb-08-21 08:22AM  
Feb-05-21 09:15AM  
Feb-04-21 01:54PM  
Feb-03-21 06:40PM  
Feb-01-21 10:28AM  
Jan-28-21 10:12AM  
Jan-27-21 11:13AM  
Jan-11-21 07:00AM  
Jan-06-21 07:00AM  
Jan-04-21 09:30AM  
Dec-31-20 12:00PM  
Dec-28-20 02:30PM  
Dec-22-20 07:00AM  
Dec-21-20 07:00AM  
Dec-15-20 05:57PM  
Nov-30-20 07:00AM  
Nov-27-20 10:00AM  
Nov-25-20 07:00AM  
Nov-06-20 10:45AM  
Oct-16-20 08:54AM  
Oct-15-20 03:13PM  
Sep-10-20 07:00AM  
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Boenisch SandraPFO and TreasurerJun 29Option Exercise4.19166,696699,163189,659Jul 01 09:45 PM
Boenisch SandraPFO and TreasurerJun 29Sale26.53166,6964,422,44522,963Jul 01 09:45 PM
FAVUS ELLIOTDirectorMay 21Option Exercise1.94145,000280,820145,000May 25 09:30 PM
FAVUS ELLIOTDirectorMay 21Sale11.70145,0001,696,2820May 25 09:30 PM
Donhauser Peter D.O.DirectorMay 17Buy10.931,00010,9302,165May 19 08:47 AM
FAVUS ELLIOTDirectorFeb 24Option Exercise3.06145,500445,390145,000Feb 26 09:31 PM
FAVUS ELLIOTDirectorFeb 24Sale12.66145,5001,841,8550Feb 26 09:31 PM
Donhauser Peter D.O.DirectorFeb 19Buy12.671,16514,7601,165Feb 23 01:22 PM